Soleno Therapeutics Stock (NASDAQ:SLNO)
Previous Close
$53.01
52W Range
$29.43 - $90.32
50D Avg
$45.78
200D Avg
$51.16
Market Cap
$2.76B
Avg Vol (3M)
$3.45M
Beta
-2.22
Div Yield
-
SLNO Company Profile
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
SLNO Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AAPG | Ascentage Pharma Group International |
| VKTX | Viking Therapeutics, Inc. |
| MIRM | Mirum Pharmaceuticals, Inc. |
| RARE | Ultragenyx Pharmaceutical Inc. |
| PRAX | Praxis Precision Medicines, Inc. |
| CELC | Celcuity Inc. |
| XENE | Xenon Pharmaceuticals Inc. |
| DYN | Dyne Therapeutics, Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| APGE | Apogee Therapeutics, Inc. |